SYNGENE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | SYNGENE | Market Cap | 16,448 Cr. | Current Price | 408 ₹ | High / Low | 761 ₹ |
| Stock P/E | 42.9 | Book Value | 115 ₹ | Dividend Yield | 0.31 % | ROCE | 12.8 % |
| ROE | 9.78 % | Face Value | 10.0 ₹ | DMA 50 | 473 ₹ | DMA 200 | 591 ₹ |
| Chg in FII Hold | -1.35 % | Chg in DII Hold | 1.21 % | PAT Qtr | 68.7 Cr. | PAT Prev Qtr | 66.2 Cr. |
| RSI | 36.5 | MACD | -18.0 | Volume | 7,98,314 | Avg Vol 1Wk | 29,25,682 |
| Low price | 381 ₹ | High price | 761 ₹ | PEG Ratio | 33.3 | Debt to equity | 0.07 |
| 52w Index | 7.05 % | Qtr Profit Var | -44.2 % | EPS | 8.22 ₹ | Industry PE | 49.5 |
SYNGENE International Ltd shows moderate potential for long-term investment. While the company has decent ROCE (12.8%) and ROE (9.78%), valuations are stretched (P/E 42.9 vs industry PE 49.5) and the PEG ratio (33.3) signals poor earnings growth relative to price. Profitability remains modest (EPS ₹8.22), and quarterly profit decline (-44.2%) raises caution. Low debt-to-equity (0.07) provides financial stability, but dividend yield (0.31%) is minimal.
📈 Ideal Entry Price Zone
An attractive entry zone would be between ₹380–₹400, near the recent low (₹381) and below the current price (₹408). This range offers valuation comfort given weak earnings momentum.
📊 Exit Strategy / Holding Period
If already holding, investors should adopt a medium-term horizon (2–3 years). Exit strategy may be considered near ₹470–₹500 if momentum improves, but long-term holding is less compelling unless profitability metrics strengthen significantly.
✅ Positive
- ROCE (12.8%) and ROE (9.78%) show moderate efficiency
- Low debt-to-equity ratio (0.07) ensures financial stability
- DII holdings increased (+1.21%), reflecting domestic institutional confidence
- EPS of ₹8.22 provides earnings visibility
⚠️ Limitation
- High P/E ratio (42.9) compared to industry PE (49.5)
- PEG ratio of 33.3 indicates poor earnings growth relative to valuation
- Dividend yield of 0.31% is negligible
- Quarterly PAT decline (₹68.7 Cr vs ₹66.2 Cr) with -44.2% variation
📰 Company Negative News
- Quarterly profit variation shows significant decline (-44.2%)
- FII holdings decreased (-1.35%), signaling reduced foreign investor interest
🌟 Company Positive News
- Stable EPS and moderate ROE/ROCE metrics
- DII holdings increased, showing domestic institutional confidence
🏦 Industry
- Biotech and pharma services sector benefits from long-term demand
- Industry PE (49.5) is higher than SYNGENE’s PE, suggesting relative undervaluation but weak growth
🔎 Conclusion
SYNGENE is a moderately strong candidate for medium-term investment, but weak earnings growth and stretched PEG ratio limit upside. Entry near ₹380–₹400 offers better risk-reward balance. Investors can hold for 2–3 years, with exit near ₹470–₹500 if profitability does not improve significantly.